



Latinx Cancer Care: It's Time for Action!



Dana-Farber
Cancer Institute

Lowie Center
for Thoracic Oncology



Duma Lab

Cancer in Latinx/Hispanic

- Cancer is the leading cause of death among Latinos, accounting for 22% of deaths
- Utilization of palliative care – 2.2% received referral to palliative care services (presented 2018)





Figure 2. Leading Sites of New Cancer Cases and Deaths Among Hispanics – 2018 Estimates



*Estimates are rounded to the nearest 100 and exclude basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. Rankings are based on modeled projections and may differ from the most recent observed data. Estimates exclude Puerto Rico.

©2018, American Cancer Society, Inc. Surveillance Research



Cancer Health Disparities

- Adverse differences between certain population groups in cancer measures:
 - Incidence
 - Stage at diagnosis
 - Mortality
 - Survivorship
 - Screening rates
 - Access to clinical trials



And many more...



Heterogeneous group

- Genetic composition
- Beliefs and perception of health
- “All grouped together”
- Geographic distribution in the U.S.



- New data from ACS: Hispanic/Latinx population in the US has the highest percentage w/o health insurance of any major racial/ethnic group.
- Notably, this group experiences a higher risk of potentially preventable, infection-related cancers.



CA:
A Cancer Journal for Clinicians

Article | Open Access |

Cancer statistics for the US Hispanic/Latino population, 2021

Kimberly D. Miller MPH , Ana P. Ortiz PhD, MPH, Paulo S. Pinheiro MD, PhD, Priti Bandi PhD, Adair Minihan MPH, Hannah E. Fuchs BS, Dinorah Martinez Tyson PhD, MPH, MA, ... [See all authors](#)

First published: 21 September 2021 | <https://doi.org/10.3322/caac.21695>

Disclosures: Kimberly D. Miller, Priti Bandi, Adair Minihan, Hannah E. Fuchs, Stacey A. Fedewa, Ahmedin M. Jemal, and Rebecca L. Siegel are employed by the American Cancer Society, which receives grants from private and corporate foundations, including foundations associated with companies in the health sector for research outside of the submitted work. The authors are not funded by or key personnel for any of these grants and their salaries are solely funded through American Cancer Society funds. Ana Patricia Ortiz reports a University of Puerto Rico/The University of Texas MD Anderson Cancer Center partnership grant (2U54CA096297-16) and consulting fees and speaker fees from Merck. The remaining authors made no disclosures.

Q & A

